Özdel Öztürk, B. Et Al. 2022. Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.. International archives of allergy and immunology , vol.183, no.5 , 526-538.

Özdel Öztürk, B., Yavuz, Z., Eraslan, D., Mungan, D., Demirel, Y. S., Aydın, Ö., ... Sin, B. A.(2022). Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.. International archives of allergy and immunology , vol.183, no.5, 526-538.

Özdel Öztürk, Betül Et Al. "Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.," International archives of allergy and immunology , vol.183, no.5, 526-538, 2022

Özdel Öztürk, Betül Ö. Et Al. "Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.." International archives of allergy and immunology , vol.183, no.5, pp.526-538, 2022

Özdel Öztürk, B. Et Al. (2022) . "Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.." International archives of allergy and immunology , vol.183, no.5, pp.526-538.

@article{article, author={Betül Özdel Öztürk Et Al. }, title={Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.}, journal={International archives of allergy and immunology}, year=2022, pages={526-538} }